Lyfegen Secures CHF 5 Million in Series A Funding to Expand Global Reach

Lyfegen, a global leader in drug rebate management technology, has secured an additional CHF 5 million in Series A funding led by TX Ventures, enabling the company to accelerate its global expansion and innovation efforts.